330 likes | 493 Views
State-of-the-art in the Surgical Treatment of Gastric Cancer in Shanghai. Department of Surgery Rui Jin Hospital School of Medicine, SJTU. Overall morbidity is declining Absolute number of pts is large Newly diagnosed GC in Shanghai > 6000 /Yr
E N D
State-of-the-art in the Surgical Treatment of Gastric Cancer in Shanghai Department of Surgery Rui Jin Hospital School of Medicine, SJTU
Overall morbidity is declining Absolute number of pts is large Newly diagnosed GC in Shanghai > 6000 /Yr Biological behavior is more aggressive in recent cases Epidemiology of Gastric Cancer in Mainland China & In Greater Shanghai
The morbidity & mortality of GC in Shanghai ( 2006 ) Male Female 在男性发病率与死亡率均居第 2位,在女性分别居第 3 与第 2位 -- Shanghai CDC, 2007--
Gastro- enterology Digestive Surgery Gastric Cancer Clinical Nutrition Radiology Pathology Chemo-radiation Institute of Digestive Surgery Multi-disciplinary Collaboration for GC Research in RJ Hospital (since 2005)
Translational Research to Improve the Outcome of Gastric Cancer Patients • New Techniques for early diagnosis of gastric cancer • Pre-operative staging • Intra-operative peritoneal hyperthermic chemotherapy(IPHC) • Multi-modality treatment of gastric cancer according to different stages
New Techniques for Early GC Screening • Symptomatic screening for high-risk population • Morphological study to delineate early gastric cancer and benign lesions • Early gastric cancer detected by fluorescence • Gastroscopy coupled with con-focal microscopy
2005-2008 Percentage of EGC in Operated GC Patients (1996~2008, RJ Hospital) Percentage of EGC in 2005-2008 : 21.6% WU YL, et al.2007
40-Yr Experience in the Surgical Treatment of Gastric Cancer in Rui-Jin Hospital
Clinical MaterialsJan. 1960 – Dec. 2000 Cases Admitted 4370 Cases Operated 3958 90.6% Cases Resected 3013 76.1% Cases Followed 3625 91.6%
No. of Resected Cases Entering into Study • Cases Analyzed 2703 • Cases Excluded 310 • Lost to Follow-Up • Accidental Death • Multiple Cancers • PTX, PNX or MX • Rate of Exclusion 10.0%
Overall Survival Rate 1960 - 2000 • Cases Resected 2703 • 5-Yr Survivors 1107 • 5-Yr SR 41.0%
Ratios of Different Stages in 2 Periods 1960-1983 1984-2000
5-Year SR During the 2 Periods % 1960-1983 1984-2000
5-Yr Survival Rate (1984-2000 Series) Radical Resection 1047 • 5-Yr Survivors 661 • Survival Rate 63.1% Palliative Resection 481 • 5-Yr Survivors 63 • Survival Rate13.1% • Overall 5-Yr SR47.4% (724/1528)
Improvement of Results Due to • Increase in ratio of Early & Middle-Stage cases • Close follow-up of high risk persons • Close cooperation between Gastroenterologists & Surgeons • Probing new parameters • Adoption of a more rational strategy
EGC ( Ia Ib ) Aims Radicalness QOL Procedures m-Ca Limited Resection EMR ESD D1 sm-Ca D2
Middle Stage( II IIIa ) Aims Radicalness Procedures ● Pre-op Staging Endoscopy EUS CT & Computerized Assessment ●Multimodality Therapy Neo-adjuvant Chemo--- Radical Op--- D2, D3 EPIC / IPHC
D2 1 7 3 9 12a 11p 8a 9 9 5 4d 4d 6 4d D1 14v the extent of standard lymph node dissection in radical gastrectomy LD/L
A comparative study on the efficacy of spleen- preserving modified D2 radical gastrectomy and D2 radical gastrectomy with splenectomy n = 61 cases n = 51 cases • n = 51 cases n = 61 cases -- Yao XX, Zhu ZG, 2010
A comparative study on the efficacy of splee-preserving modified D2 radical gastrectomy and D2 radical gastrectomy with splenectomy Conclusion: The efficacy of modified D2 radical total gastrectomy with spleen-preserving for patients with gastric cancer in the upper third, upper and middle third or entire stomach is similar to that of D2 radical total gastrectomy with splenectomy, and the spleen-preserving procedure is associated with decreased postoperative complication and improved survival. -- Yao XX, Zhu ZG, 2010
IPHC Procedure • Double-pump closed-circuit circulation ; volume:5-6 L • Thermo-control:water-bath, 43.0℃±1.0℃ • Input Temperature: 44.0℃~45.0℃ • Output Temperature: 40.0℃~42.0℃ • Velocity: 500 ~ 800 ml/min • 4 sites for thermo-detector • Duration:1h • Chemo-agents: CDDP 50mg/L,MMC 5mg/L ZHU ZG et al., 2006
Overall Survival Rates ZHU ZG et al., 2006
Survival Benefits of Prophylactic IPHC ZHU ZG et al., 2006
Survival Benefits of Therapeutic IPHC P<0.05 ZHU ZG et al., 2006
Late Stage ( IIIb IV ) Aims Prolong SR & QOL Procedures Cyto-reductive Op If Feasible Multi-Modality Therapy